Involvement of glycogen debranching enzyme in bladder cancer (Review)

Weinhaus,Benjamin; Guin,Sunny

doi:10.3892/br.2017.907

Involvement of glycogen debranching enzyme in bladder cancer (Review)

Authors:
- Benjamin Weinhaus
- Sunny Guin
View Affiliations

Affiliations: Gundersen Medical Foundation, La Crosse, WI 54601, USA
Published online on: May 9, 2017 https://doi.org/10.3892/br.2017.907
Pages: 595-598

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bladder cancer is the most common malignancy of the urinary system, however the molecular pathways underlying this disease are incompletely understood. To understand new regulators of bladder cancer progression, the authors carried out a functional genomic screen which identified glycogen debranching enzyme (AGL) as a novel regulator of bladder cancer growth. Glycogen debranching enzyme is involved in glycogen breakdown and germline loss of function mutation of this gene leads to glycogen storage disease type III. To the best of the authors' knowledge, the present study is the first to demonstrate that loss of AGL leads to aggressive bladder tumor growth. AGL mRNA and protein expression in bladder tumors serve as a prognostic marker for patients. Interestingly, AGL's participation in regulating tumor growth is independent of its enzymatic function and involvement with glycogen metabolism in general. Detailed metabolomics and transcriptomic analysis indicated that increases in glucose metabolism, glycine synthesis driven by serine hydroxymethyltransferase 2 and increases in hyaluronic acid synthase 2‑driven HA synthesis are major contributors of aggressive bladder tumor growth with loss of AGL. However, the detailed mechanism of how AGL regulates the above mentioned metabolic and genetic pathways is unknown and is being investigated. The present review focuses on AGL's involvement in bladder cancer.

View Figures

View References

1	Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
2	Ariazi EA, Ariazi JL, Cordera F and Jordan VC: Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 6:181–202. 2006. View Article : Google Scholar : PubMed/NCBI
3	Waqar SN and Morgensztern D: Precision medicine in lung cancer: The battle continues. J Thorac Dis. 8:2991–2993. 2016. View Article : Google Scholar : PubMed/NCBI
4	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
5	Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al: PROFILE 1014 Investigators: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
6	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
7	Zhuo C, Li X, Zhuang H, Tian S, Cui H, Jiang R, Liu C, Tao R and Lin X: Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: A network meta-analysis. Oncotarget. 7:82567–82579. 2016.PubMed/NCBI
8	National Cancer Institute, . A Snapshot of Bladder Cancer. https://www.cancer.gov/research/progress/snapshots/bladderNovember 5–2014
9	Guin S, Pollard C, Ru Y, Lew C Ritterson, Duex JE, Dancik G, Owens C, Spencer A, Knight S and Holemon H: Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. J Natl Cancer Inst. 106:pii: dju0622014. View Article : Google Scholar
10	Adeva-Andany MM, González-Lucán M, Donapetry-García C, Fernández-Fernández C and Ameneiros-Rodríguez E: Glycogen metabolism in humans. BBA Clin. 5:85–100. 2016. View Article : Google Scholar : PubMed/NCBI
11	Dagli A, Sentner CP and Weinstein DA: Glycogen Storage Disease Type IIIGeneReviews^® [Internet]. Pagon RA, Adam MP, Ardinger HH, et al: University of Washington; Seattle, WA: pp. 1993–2017
12	Lew C Ritterson, Guin S and Theodorescu D: Targeting glycogen metabolism in bladder cancer. Nat Rev Urol. 12:383–391. 2015. View Article : Google Scholar : PubMed/NCBI
13	Hebbring SJ, Chai Y, Ji Y, Abo RP, Jenkins GD, Fridley B, Zhang J, Eckloff BW, Wieben ED and Weinshilboum RM: Serine hydroxymethyltransferase 1 and 2: Gene sequence variation and functional genomic characterization. J Neurochem. 120:881–890. 2012.PubMed/NCBI
14	Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB and Mootha VK: Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 336:1040–1044. 2012. View Article : Google Scholar : PubMed/NCBI
15	Guin S, Ru Y, Agarwal N, Lew CR, Owens C, Comi GP and Theodorescu D: Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis. Clin Cancer Res. 22:1274–1283. 2016. View Article : Google Scholar : PubMed/NCBI
16	Karbownik MS and Nowak JZ: Hyaluronan: Towards novel anti-cancer therapeutics. Pharmacol Rep. 65:1056–1074. 2013. View Article : Google Scholar : PubMed/NCBI
17	Tammi RH, Passi AG, Rilla K, Karousou E, Vigetti D, Makkonen K and Tammi MI: Transcriptional and post-translational regulation of hyaluronan synthesis. FEBS J. 278:1419–1428. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wang A, de la Motte C, Lauer M and Hascall V: Hyaluronan matrices in pathobiological processes. FEBS J. 278:1412–1418. 2011. View Article : Google Scholar : PubMed/NCBI
19	Lokeshwar VB, Mirza S and Jordan A: Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res. 123:35–65. 2014. View Article : Google Scholar : PubMed/NCBI
20	Nagy N, Kuipers HF, Frymoyer AR, Ishak HD, Bollyky JB, Wight TN and Bollyky PL: 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol. 6:1232015. View Article : Google Scholar : PubMed/NCBI
21	Nikitovic D, Kouvidi K, Kavasi RM, Berdiaki A and Tzanakakis GN: Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer. Curr Drug Deliv. 13:500–511. 2016. View Article : Google Scholar : PubMed/NCBI
22	Dicker KT, Gurski LA, Pradhan-Bhatt S, Witt RL, Farach-Carson MC and Jia X: Hyaluronan: A simple polysaccharide with diverse biological functions. Acta Biomater. 10:1558–1570. 2014. View Article : Google Scholar : PubMed/NCBI
23	Orian-Rousseau V: CD44 Acts as a Signaling Platform Controlling Tumor Progression and Metastasis. Front Immunol. 6:1542015. View Article : Google Scholar : PubMed/NCBI
24	Misra S, Hascall VC, Markwald RR and Ghatak S: Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Front Immunol. 6:2012015. View Article : Google Scholar : PubMed/NCBI
25	Maxwell CA, McCarthy J and Turley E: Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual oncogenic functions? J Cell Sci. 121:925–932. 2008. View Article : Google Scholar : PubMed/NCBI
26	Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, Escudero DO, Dhir N and Altman N: Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res. 70:2613–2623. 2010. View Article : Google Scholar : PubMed/NCBI
27	Yates TJ, Lopez LE, Lokeshwar SD, Ortiz N, Kallifatidis G, Jordan A, Hoye K, Altman N and Lokeshwar VB: Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer. J Natl Cancer Inst. 107:djv0852015. View Article : Google Scholar : PubMed/NCBI
28	Oldenburg D, Ru Y, Weinhaus B, Cash S, Theodorescu D and Guin S: CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL). BMC Cancer. 16:7132016. View Article : Google Scholar : PubMed/NCBI